ERBB2 and neoplasm: Recently, investigators from the CALGB 9344 randomised adjuvant trial (Henderson et al, 2003) reported that patients with HER2-positive tumours derived significant benefit from the addition of paclitaxel to a doxorubicin–cyclophosphamide regimen regardless of ER status, whereas there was no additional benefit in HER2-negative, ER-positive cases (Hayes et al, 2007).